Remove tag liver
article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 million in the US and just under €2 million in Europe, which the company says is justified by its dramatic benefits when given as a one-shot therapy to patients with SMA. Pause in UK access.

article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

There are three primary reasons for the failure of complex medicines: Biodistribution – due to physiological factors, complex formulations often preferentially target the liver, and as a result, many of the clinically approved complex medicines target liver disease. Physical characterisation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 105
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 98